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Abstract
In testicular germ cell tumour (GCT), imaging plays a central role in assessment of tumour bulk, sites of metastases,
monitoring response to therapy, surgical planning and accurate assessment of disease at relapse. The primary modality
used for imaging patients with GCT is computed tomography (CT) but plain film radiography, ultrasound, magnetic
resonance imaging (MRI) and positron emission tomography (PET) may all have roles to play. This article reviews
the role of imaging of testicular germ cell tumours.
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Introduction
Testicular germ cell tumours (GCT) are an increasingly
common group of tumours, particularly in young males.
The success of current management strategies is such
that the majority of patients can expect to be cured.
This success hinges on accurate disease assessment and
application of chemotherapy and radiotherapy. Serum
markers can be useful surrogate markers of disease
activity, but they cannot accurately assess disease bulk or
locate sites of tumour spread. For these purposes imaging
is invaluable and now plays an integral role not only
in assessment of tumour bulk and sites of metastases
but also in monitoring response to therapy, surgical
planning and accurate assessment of disease at relapse.
The primary modality used for imaging patients with
these tumours is computed tomography (CT) but plain
film radiography, ultrasound and magnetic resonance
imaging (MRI) also have roles to play. Positron emission
tomography (PET) scanning is now being more widely
used but its optimal role has yet to be agreed. This article
reviews the literature relating to imaging in testicular
germ cell tumours. It covers the role of imaging from
diagnosis through staging to post-treatment monitoring
and surveillance and evidence for the use of imaging.
Diagnosis
The diagnosis of germ cell tumours (GCT) is made
by a biopsy or at orchidectomy. Testicular GCT most
commonly presents as a painless palpable mass (up to
95% of cases) [1]. In up to 10% of cases, it may present
with dull scrotal ache, pain or acute fever [2]. In patients
with retroperitoneal metastases or disseminated disease,
backache, malaise, lethargy and other systemic features
may be the presenting findings [3]. Imaging is largely used
to confirm the presence of disease and assess its extent.
Testicular ultrasound (which should be performed
using a 7.5 MHz probe) is used in primary assessment of
the testes to confirm diagnosis, to distinguish from other
scrotal abnormalities and to screen for abnormalities
such as microlithiasis in the contralateral testis [2,4–6].
Sonographically, testicular tumours are usually well
defined and hypoechoic relative to the normal testicle,
although some may display a heterogeneous echotexture,
calcification or cystic change (Fig. 1). Tumours may
display increased vascularity on colour and power
Doppler with respect to surrounding normal testicular
tissue but this is not specific and may not be demonstrated
in small tumours [7]. Ultrasound cannot be used to reliably
differentiate between tumour types. For this purpose,
MRI may be useful [8,9].
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Table 1 TNM staging classification of testicular tumours [10]
Primary tumour
The extent of the primary tumour is classified after radical orchidectomy (pT)
pTX Primary tumour cannot be assessed (if no radical orchidectomy has been performed, TX is used)
pT0 No evidence of primary tumour (e.g. histological scar in testis)
pTis Intratubular germ cell neoplasia
pT1 Tumour limited to testis and epididymis without vascular/lymphatic invasion; tumour may invade into the tunica albuginea but not the
tunica vaginalis
pT2 Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour extending through tunica albuginea with
involvement of tunica vaginalis
pT3 Tumour invades spermatic cord with or without vascular/lymphatic invasion
pT4 Tumour invades scrotum with or without vascular/lymphatic invasion
Regional lymph nodes
Clinical involvement
NX Regional nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis with a lymph node mass ≤2 cm in greatest dimension or multiple lymph nodes none >2 cm in greatest dimension
N2 Metastasis with a lymph node mass >2 cm but <5 cm in greatest dimension, or multiple lymph nodes, any one mass >2 cm but ≤5 cm in
greatest dimension
N3 Metastasis with a lymph node mass >5 cm in greatest dimension
Pathological involvement
pN0 No regional lymph node metastases
pN1 Metastasis with a lymph node mass ≤2 cm in greatest dimension and 5 or fewer positive nodes, none >2 cm in greatest dimension
pN2 Metastasis with a lymph node mass >2 cm but ≤5 cm in greatest dimensions; or more than five nodes positive, none >5 cm; or evidence
of extranodal extension of tumour
pN3 Metastasis with a lymph node mass >5 cm in greatest dimension
Distant metastases
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Non-regional lymph node or pulmonary metastasis
M1b Distant metastasis other than to non-regional lymph nodes and lungs
Staging
Once a diagnosis of testicular germ cell tumour has been
made, assessment of disease extent must be performed
prior to initiating therapy. The European Germ Cell
Cancer Consensus Group (EGCCCG) recommend that
TNM staging be used [10] (Table 1) and that patients be
categorised using the International Germ Cell Cancer
Collaborative Group (IGCCCG) classification which
stratifies patients into good, intermediate and poor
prognostic groups. This latter classification is based on
histology, location of primary tumour and metastases and
levels of serum markers (Table 2) [11]. A further staging
classification, devised at The Royal Marsden Hospital
(UK) and widely used in the UK and Europe, is shown
in Table 3.
When staging tumours, knowledge of the patterns of
spread enables prediction of sites of disease and may
improve the accuracy of assessment. Testicular tumours
spread via vascular or lymphatic invasion (Figs. 2–5).
Vascular spread is most commonly to the lungs. Lung
metastases may vary in appearance with respect to the
histology of the primary tumour; those from NSGCT
appear as multiple small peripheral nodules whereas
seminoma metastases tend to be larger masses (Fig. 2).
Other sites of metastatic spread include the brain (most
common in trophoblastic teratomas), bones and liver
(Figs. 3 and 4). Other sites of metastases, though rarely
seen and usually only in the setting of advanced disease,
include the adrenals, kidneys, spleen, pleura, pericardium
and peritoneum.
Figure 1 Testicular carcinoma. Ultrasound demon-
strating heterogeneous echotexture throughout the
testicle.
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Table 2 International Germ Cell Consensus classification [11]
Non-seminoma
Good prognosis: all of the following
—AFP <1000 ng/ml and HCG <5000 iu/l (1000 ng/ml) and LDH <1.5 × upper limit of normal (N) and
—Non-mediastinal primary
—No non-pulmonary visceral metastases (NPVM)
Intermediate prognosis: all of the following
—AFP 1000–10 000 ng/ml, or HCG 5000–50 000 iu/l, or LDH 1.5–10 × N and
—Non-mediastinal primary site and
—No NPVM
Poor prognosis: any of the following
—AFP >10 000 ng/ml or HCG >50 000 iu/l or LDH >10 × N or
—Mediastinal primary site or
—NPVM
Seminoma
Good prognosis
—No NPVM
—Any primary site
—Normal AFP, any HCG, any LDH
Intermediate prognosis
—NPVM present
Note: AFP = alphafetoprotein; B-HCG = B-human chorionic gonadotrophin; LDH = lactate dehydrogenase; CNS = central nervous system.
Table 3 The Royal Marsden Hospital staging classifi-
cation for testicular germ cell tumours [30]
Stage Definitions
I No evidence of metastases
IM Rising serum markers with no other evidence of metastases
II Abdominal node metastases
A <2 cm in diameter
B 2–5 cm in diameter
C >5 cm in diameter
III Supradiaphragmatic node metastases
M Mediastinal
N Supraclavicular cervical axillary
O No abdominal node metastases
ABC Node size defined as in Stage II
IV Extralymphatic metastases
Lung
L1 ≤3 metastases
L2 >3 metastases all <2 cm in diameter
L3 >3 metastases, one or more >2 cm in diameter
H+ Liver metastases
Br+ Brain metastases
Bo+ Bone metastases
Lymphatic spread reflects the retroperitoneal
embryological origin of the testis. Spread occurs via
lymphatic channels which pass through the inguinal ring
(accompanying the spermatic cord and testicular vessels)
to enter retroperitoneal nodes (Fig. 5). Right-sided
tumours normally spread to right-sided nodes around the
IVC (most commonly lower retroperitoneal, aortocaval or
paracaval). Left-sided tumours normally spread to lymph
nodes on the left, adjacent to the aorta (most commonly
just below the left renal hilum). In the absence of bulky
ipsilateral adenopathy, contralateral spread is unusual,
and if seen as the only site of metastasis, histological
proof of tumour involvement should be sought prior
to instigation of therapy [12]. Pelvic adenopathy is also
Figure 2 Lung metastases. CT image showing
multiple lung masses in a patient with metastatic
testicular seminoma.
uncommon in the absence of bulky disease elsewhere
or history of maldescent or previous scrotal surgery [13].
Echelon nodes, which are sites of nodal disease, identified
more frequently at relapse than during primary disease,
have been described [14]. On the right the echelon node is
sited laterally between the L1 and L3 vertebrae [15]. On
the left a similar node has been described as lying on
iliopsoas [16].
Nodal disease superior to the level of the renal
hila occurs via direct spread. In cases of seminoma
spread of disease above the diaphragm may occur via
the thoracic duct into the posterior mediastinum. In
NSGCT, however, spread is more random involving
the anterior mediastinum, aortopulmonary window, hilar,
supraclavicular and neck lymph nodes but excluding the
posterior mediastinum and subcarinal regions [17].
The primary imaging modality currently used for
staging disease is computed tomography (CT). Its
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Figure 3 Metastatic non-seminomatous germ cell tumour. Contrast-enhanced CT shows (a) liver metastasis
and (b) the left testicular tumour (arrow).
(a) (b)
Figure 4 Brain metastasis. (a) Contrast-enhanced CT showing an enhancing mass (arrow) in the right
parietal lobe with surrounding oedema. (b) FLAIR MR image following treatment shows the lesion to be
smaller and the surrounding oedema to have resolved.
overall accuracy approaches 80% [18]. Current EGCCCG
guidelines state that patients should receive contrast-
enhanced CT of thorax, abdomen and pelvis [19]. The
exception to this is in patients with seminoma and no
retroperitoneal disease, where chest radiography (in place
of thoracic CT) is thought sufficient to assess the thorax
for metastases [20].
Computed tomography (CT)
Overall, CT has been shown to be the most sensitive
method of assessing metastatic disease in the thorax,
abdomen and pelvis, though it is recognised that it may
understage disease in up to 25% of cases [21]. It has also
been found to be the most sensitive method of assessing
supraclavicular, mediastinal and pleural disease [22–28].
With respect to thoracic imaging, use of multidetector
CT has not been shown to increase nodule detection
when compared to that using single-slice CT for slice
thicknesses of 5 mm [29]. However, the ability to produce
submillimetre sections will undoubtedly increase the
sensitivity of multislice CT for nodule detection.
Lymph node metastases are usually of soft tissue
density. Large volume seminomatous disease may, how-
ever, have a central low density secondary to necrosis,
whereas in large volume NSGCT complex cysts allied
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(a) (b)
Figure 5 Retroperitoneal lymphadenopathy. Contrast-enhanced CT (a) before and (b) after chemotherapy
shows retroperitoneal lymphadenopathy (arrow) encasing the aorta. The post-chemotherapy scan shows
significant reduction in the burden of retroperitoneal lymphadenopathy.
with foci of soft tissue may be seen [30]. In large volume
disease the diagnosis is rarely in doubt. Assessment of
small volume lymphadenopathy, which has significant
implications for patient staging and management, is
unfortunately the Achilles’ heel of CT. The detection of
microscopic deposits of tumour in normal-sized nodes
and the distinction between tumoral and inflammatory
adenopathy are beyond the scope of CT. In light of these
handicaps it comes as no surprise that false negative CT
examinations occur, thus limiting its diagnostic accuracy.
CT is unable to identify small volume disease in normal-
sized nodes in up to 30% of patients with GCT [31–35].
Studies performed to assess the effect of different
thresholds of significance for lymph node size have been
performed [36,37]. Essentially, they confirm the logical
notion that, by reducing the lymph node size accepted
as normal, the likelihood of detecting positive nodes
increases, but the specificity of the test decreases.
It has been shown that by using 10–15 mm as the
upper limit of normal, up to 44% of scans were false
negative [38–40]. A further complication of trying to
standardise upper limits of normal is that normal nodes in
the superior retroperitoneum are smaller than those in the
inferior retroperitoneum on CT [41–43]. Standardization of
normality as such has not been agreed; thus institutions
vary in their practice. An assessment schema is given
(Table 4) [30]. For practical purposes a cut-off of 10 mm is
used to differentiate between normal and abnormal lymph
nodes. Those measuring between 8 and 10 mm are treated
as suspicious. These measurements must, however, be
taken in the overall context of the patient’s situation such
as risk of disease, marker levels, etc. Laterality of the
tumour is an additional consideration. Sites suspicious of
disease warrant further investigation; this could include
tissue sampling, biochemical markers, additional imaging
such as PET scanning (see below) and further follow-up
imaging.
Table 4 Lymph node size at various anatomic sites:
short axis diameter, upper limits of normal
Site Group Short axis size
(mm)
Head and neck Cervical 10 (<10 mm with
central necrosis)
Axilla 10
Mediastinum Subcarinal 12
Paracardiac 8
Retrocural 6
All other sites 10
Abdomen Gastrohepatic ligament 8
Porta hepatis 8
Portacaval 10
Coeliac axis to renal artery 10
Renal artery to aortic bifurcation 12
Pelvis Common iliac 9
External iliac 10
Internal iliac 7
Obturator 8
For the detection of disease beyond the chest, abdomen
and pelvis, CT of the brain is not undertaken as part of
routine staging in all patients but is indicated in those with
high-risk factors (e.g. multiple lung metastases, HCG >
10 000) and in patients with suspected metastatic disease
on clinical grounds [44,45]. Brain metastases are often
haemorrhagic and usually demonstrate enhancement after
intravenous contrast administration (Fig. 4) [30].
Ultrasound
Ultrasound is not routinely used in staging of disease.
Assessment of retroperitoneal and pelvic nodes has been
shown to be not as reliable when compared to CT
or MRI [19]. Indeed, it has been reported that up to
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17% of small volume disease may be missed. However,
ultrasound is useful in the assessment of solid intra-
abdominal organs, e.g. the liver, and as a guide for needle
placement during biopsy.
Magnetic resonance imaging (MRI)
Use of MRI to date has been limited in part due to its
long examination times, high cost and low availability.
However, with the advent of new, shorter sequences
and techniques and increasing MRI availability, it is
likely that there will be an increase in its use. The use
of MRI in staging testicular GCT is emerging. When
compared to CT, MRI is known to have better soft
tissue contrast resolution and be at least as accurate in
detection of retroperitoneal lymph nodes [46] though it
is not as accurate in detecting lung metastases [47,48].
MRI is of use in detection and characterisation of
central nervous system, musculoskeletal and hepatic
metastases. Furthermore it has also been found to be
useful in demonstration of IVC tumour invasion, enteric
fistulae [8,9] and demonstration of vascular anatomy in
patients prior to retroperitoneal lymph node surgery. MRI
may also be used in those patients where intravenous
contrast cannot be given and as a problem solving
technique for equivocal CT findings [19].
Recently, MR imaging with lymphotrophic nanoparti-
cles (LNMRI) has been shown to be an effective method
for evaluating lymph nodes in cancers [49–55]. Lymphatic
targeting has been shown to result from slow extrava-
sation of nanoparticles into the interstitial space, from
which they are transported to lymph nodes by lymphatics.
Within lymph nodes, these nanoparticles are internalized
into macrophages, resulting in intracellular trapping and
subsequent changes in magnetic properties by MR. A
recent study showed that lymphotrophic nanoparticle-
enhanced MRI demonstrated higher sensitivity and
specificity for detecting nodal metastases when compared
with plain MRI alone. Many nodes larger than 10 mm
were benign (32%) and were accurately characterized by
LNMRI. The two nodes in that study that were falsely
positive were larger than 10 mm and had >50% foci of
hyalinization. These areas of hyalinization appeared as
focal defects on LNMRI, mimicking metastatic nodes. It
was also shown that LNMRI showed a high degree of
accuracy in detecting metastases in nodes smaller than
10 mm which would otherwise be considered benign on
the basis of traditional size criteria [50].
Positron emission tomography (PET)
PET scanning utilises the differentially greater uptake
of fluorine-18-labelled fluorodeoxyglucose (18FDG) in
malignant cells (owing to their higher metabolic rate)
than normal tissue to enable tumour detection. Aside
from mature differentiated teratomas (which have a
relatively low metabolic rate) most tumours (and their
metastases) demonstrate avid 18FDG uptake. With
respect to testicular tumours it has been shown that
seminomatous lesions have a significantly higher FDG
uptake than non-seminomatous germ cell tumours, as
expressed by the standard uptake values (SUV) [56,57].
The use of PET is widely advocated as it has been
shown that the sensitivity of PET is greater than CT (but
with similar specificity) [58,59]. In one study the sensitivity
and specificity of PET was reported to be 87% and
94%, respectively, compared to 73% and 94% for CT [60].
It has also been stated that the use of PET can alter
management in up to 57% of patients [61] although this
is not a universally held view [62].
The role of PET in primary staging is minimal if
metastatic disease has already been diagnosed. However,
as PET images include a greater body area, it may
define sites of disease outside the scope of that seen
on routine CT scanning. This can have repercussions
on management [59]. Identification of sites of metastases
have been shown repeatedly to be more accurately
performed by PET than CT [63]. However, its poor
detection of small volume (sub-centimetre) disease
remains a concern.
A possible use of PET is in those patients with
raised tumour marker levels but no definite disease on
conventional imaging. Hain et al. reviewed cases of
patients with raised marker levels (including those with
residual mass) [64]. They found that in all but one case
PET identified the site of disease. In their study, five
false negative PET results were found. Out of these,
three cases had no abnormality on any imaging modality.
During follow-up of these patients, it was found that
PET scans were the first imaging modality to identify
the site of recurrence. As a result of this it was suggested
that in the presence of raised marker levels and negative
imaging (including negative PET), the most appropriate
follow-up imaging may be repeat PET. The use of PET
to predict relapse in patients with clinical stage I non-
seminomatous germ cell tumour has been investigated
by the Medical Research Council (MRC) in the UK in
the TE22 study. The study showed that PET identified a
proportion of patients with disease not detected by CT;
however, the relapse rate among PET-negative patients
remains high. The study results therefore suggest that
18FDG-PET scanning is not able to identify patients at
sufficiently low risk of relapse to replace other treatment
options in this setting [65].
Surveillance
In patients with stage I disease surveillance is a
common management pathway. Overall, approximately
30% of patients will relapse [66–68]. Vascular or lymphatic
invasion is the most powerful predictor of relapse;
the absence of yolk sac elements and the presence of
undifferentiated cells are also independent prognostic
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variables [69]. In the prospective TE04 trial, 45% of those
that relapsed did not have raised markers at the time
of discovery of recurrent disease. Sixty-one percent of
relapses occurred in the para-aortic nodes and 10% in
mediastinal or supraclavicular nodes. Ninety-five percent
of those who did relapse were in the IGCCCG good
prognostic group and overall survival free from germ cell
tumour was 99% [11]. As relapse is most frequent in the
first year after diagnosis (up to 80%) the number of scans
is maximal during this time. Surveillance is performed
rigorously with clinical follow-up, chest radiography,
serum marker analysis and CT. Serial imaging of the
thorax and abdomen is routinely performed.
The value of chest CT above chest radiography has
been studied. In a series of 168 stage I NSGCT patients
on surveillance in whom chest X-ray rather than chest
CT was performed [70]. Nineteen percent (42 patients) of
these patients relapsed of which 8/42 relapsed with chest
disease. Seven out of eight of these latter patients had
evidence of disease elsewhere which was identified on
abdominal CT. The one patient in this series who had only
chest disease at relapse was clearly diagnosed by chest
radiography. This led the authors to conclude that chest
imaging with CT would not have changed the prognosis
of those that relapsed in the chest in their study [69].
The role of pelvic CT has also been called into
question. In one series of patients with testicular germ
cell tumours pelvic lymphadenopathy was seen in 16 of
167 patients (9.6%). The presence of bulky para-aortic
lymphadenopathy was the only significant predictor for
pelvic disease and was present in 11 of 16 patients.
In the absence of this or other risk factors for pelvic
disease (previous scrotal or inguinal surgery, maldescent,
tunica vaginalis invasion, retroperitoneal lymph node
dissection or bulky abdominal nodes), routine pelvic
CT for patients on surveillance for stage I disease may
constitute unnecessary radiation [25].
Centres vary in their preference, but most will scan
patients between two and six times during the first year.
As yet no consensus on optimal management has been
derived but it is seen that those centres that scan more
frequently do not detect relapse at a significantly earlier
stage. Indeed in one study of 46 patients, all relapses
detected after the 3 month CT were picked up by clinical
suspicion, raised tumour markers or chest X-ray [71]. The
question of whether more frequent CT results in earlier
diagnosis of relapse and whether this has any outcome
on survival still remains to be conclusively answered.
Indeed, early results of the MRC TE08 study have not
detected any advantage for a five scan schedule over a
two scan schedule (NCRI meeting, October 2005).
The potential benefit of repeated scanning must be
weighed against the financial and health costs of more
frequent scans. A thoracic CT gives a radiation dose
equivalent to 400 chest radiographs (8 vs. 0.02 mSv),
while for a chest and abdomen CT the dose is increased
to approximately 20 mSv (a dose equivalent to 1000
chest radiographs). This results in a 1 : 1000 lifetime
risk of a second cancer/leukaemia in a 25-year-old over
the subsequent 40 years. Another approach to reducing
radiation exposure is to use alternative technology. The
use of ultrasound and magnetic resonance imaging (MRI)
has therefore been suggested in surveillance programmes.
Ultrasound is not as reliable as CT or MR imaging in the
assessment of abdominal para-aortic nodes. Limited data
suggest that MR imaging may be used instead of CT for
abdominal disease [46].
Positron emission tomography (PET) is an attractive
alternative modality to improve surveillance but as
discussed above the MRC TE22 protocol suggests the
added value of PET scan may be limited [65].
Figure 6 Mature teratoma differentiated in retro-
crural node (arrow). Contrast-enhanced CT shows
low density lesion in the right retrocrural region.
Assessing response to therapy
The EGCCCG guidelines state that radiological restag-
ing must be performed after completion of first-line
chemotherapy. However, in patients with slow tumour
marker decline or clinical evidence of progression,
restaging should be performed earlier.
Chest radiographs are useful screening tools and are
often used in the routine follow-up of early-stage patients
and those in complete remission following chemother-
apy [72]. They enable detection and surveillance of lung
parenchymal nodules 1 cm (or greater) in size, pleurally
based masses and effusions and mediastinal masses. In
a study designed to investigate the predictive capacity
of chest radiography, 288 patients were retrospectively
studied. Thirty-three cases of relapse were found but none
were identified by chest radiography [73]. Despite this,
their relatively low radiation burden and cost continue to
make them attractive tools for follow-up studies.
CT is the primary imaging modality for assessing
response of disease to treatment. Reduction in size of
metastases is the primary change found on CT indicating
response to therapy even if malignant cells persist within
the residual tissue (Fig. 5). In addition to size, CT
can help assess residual masses post-chemotherapy by
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Figure 7 Non-seminomatous germ cell tumour. (a) Coronal and (b) axial images on 18-FDG enhanced
PETCT and (c) iodinated contrast enhanced CT showing a large metabolically active retroperitoneal mass
(arrows).
assessing changes in appearance. Cystic and fatty change
which is well assessed using CT have been associated
with mature differentiated teratoma and may indicate the
need for surgical removal (Fig. 6) [74–76].
Seminoma is extremely sensitive to chemo- and radio-
therapy, such that residual mass post treatment usually
only consists of fibrosis and necrosis. Calcification may
also be found within post-treatment tissue [77]. The CT
findings may be allied to reduction in serummarker levels
and reduction in avidity of uptake on PET scanning.
Treated lung metastases may resemble irregular scars
in the region of the previous metastases. In some cases
they may also be seen to cavitate [78]. Interval CT
scanning during and following completion of therapy
is important to assess the response [79]. It also allows
the selection of patients who may benefit from surgi-
cal lymphadenectomy (traditonally those with residual
masses greater than 1 cm) [80]. In those patients with
large-volume disease the use of CT and MRI has been
shown to be useful in planning an operative approach [81].
PET may have a role in the assessment of residual
masses after chemotherapy. Cremerius et al. reviewed
PET scans in patients with seminoma after treatment [56].
They reported that PET had 90% sensitivity for detecting
residual disease. These results indicate that PET may
be of value in selecting patients with seminoma for
radiotherapy. The SEMPET trial (where PET was used
to assess residual disease in patients with seminoma
who were on chemotherapy) showed that PET imaging
was more accurate than other assessment modalities [82].
In that study, PET was performed in all patients with
residual masses ≥1 cm within 4–12 weeks of completion
of chemotherapy. The results were compared to histo-
logical analysis of tumour viability or CT evidence of
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progression. They reported that PET correctly identified
all cases of residual tumour in lesions >3 cm and in
95% of cases with lesions ≤3 cm. This gave an overall
specificity and sensitivity for 100% and 80% respectively
for PET, compared with 74% and 70% for CT. A further
recent study reported that only 4 of 47 lesions <3 cm
(8.5%) were viable, whereas 11 of 27 lesions ≥3 cm
(41%) were viable [83]. This led the authors to conclude
that using a solely CT-based surgical strategy would have
resulted in over-treatment of nearly 60% of the patients.
They suggest that, in lesions ≥3 cm, a negative PET scan
may justify surveillance of the patient, since no false
negative PET scan was registered in lesions ≥3 cm in
the present study. In lesions <3 cm, only one of four
viable lesions showed FDG uptake. As there were no false
positive results in this group either, it was suggested that a
positive PET scan, even in small lesions, is highly specific
for tumour viability.
In NSGCT patients with residual masses PET is less
useful. PET can differentiate between viable disease and
fibrosis (Fig. 7) [56,64,84]. The sensitivity and specificity
of PET in the largest (75 scans in 55 men) series was
88% and 95%, respectively, with high negative predictive
value (NPV) and positive predictive value (PPV) of
90% and 96%, compared with a PPV for CT in this
circumstance of 56% [64]. However, its use is limited in
this setting as differentiated teratoma (MTD) has variable
low or no uptake and cannot be distinguished from
fibrosis or necrosis. The crucial decision here is whether
a marker response requires surgery or not and PET is
unable to help these patients.
The use of PET to predict response to treatment is
uncertain. In contrast to salvage treatment one study
found that PET was found more sensitive than CT or
serum markers, 100% vs. 59% and 48%, respectively [85].
Though PET was shown not to be as specific as
serum tumour markers for this purpose (78% vs. 100%,
respectively) it did correctly predict all patients in this
study who failed therapy. The overall accuracies of PET,
CT and serum markers for prediction of response to high-
dose chemotherapy in this study were 91%, 59% and
48%, respectively. There is little information to suggest
that PET has a role in first-line treatment when standard
assessment tools are successful.
Conclusion
Testicular germ cell tumours have been increasing in
incidence and now represent 1% of all male tumours.
Tumour presence is normally clinically diagnosed and
confirmed by raised levels of serummarkers. Imaging can
confirm tumour presence but is most useful in assessing
the sites of metastases. The most common sites of spread
are to retroperitoneal lymph nodes and lung parenchyma.
Staging of tumours (which is an integral process in
establishing prognosis and therapy) is largely performed
using CT. Recent studies have shown that the use of
PET in specific scenarios may have significant advantage
over CT. MR imaging is used in those patients with
neurological disease or where intravenous contrast agent
cannot be administered or as an aid to problem solving
for equivocal CT.
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